TY - JOUR
T1 - In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder
AU - Gidaya, Nicole B.
AU - Lee, Brian K.
AU - Burstyn, Igor
AU - Yudell, Michael
AU - Mortensen, Erik L.
AU - Newschaffer, Craig J.
N1 - Funding Information:
Acknowledgments We thank Karyn Heavner, Ph.D., for assisting with data management, and implementation of Monte Carlo simulations. Fees to access Denmark’s national’s registers were funded by Drexel University Department of Epidemiology and Biostatistics (Dr. Newschaffer). Dr. Gidaya’s travel was funded in part through a travel award through Drexel University.
Publisher Copyright:
© Springer Science+Business Media New York 2014.
PY - 2014/10
Y1 - 2014/10
N2 - We investigated whether there is an association between increased risk for autism spectrum disorders (ASD) and selective serotonin reuptake inhibitors (SSRIs) used during pregnancy. This study used Denmark’s health and population registers to obtain information regarding prescription drugs, ASD diagnosis, and health and socioeconomic status. There were 1.5 % of cases and 0.7 % of controls exposed to SSRIs during the pregnancy period, and higher effect estimates observed with longer use. We found evidence that in utero exposure to SSRIs increases a child’s risk associated with ASD. These results, while adding to the limited knowledge on prenatal pharmacological exposures as potential ASD risk factors, need to be balanced against the benefits of indicated medication use by pregnant mothers.
AB - We investigated whether there is an association between increased risk for autism spectrum disorders (ASD) and selective serotonin reuptake inhibitors (SSRIs) used during pregnancy. This study used Denmark’s health and population registers to obtain information regarding prescription drugs, ASD diagnosis, and health and socioeconomic status. There were 1.5 % of cases and 0.7 % of controls exposed to SSRIs during the pregnancy period, and higher effect estimates observed with longer use. We found evidence that in utero exposure to SSRIs increases a child’s risk associated with ASD. These results, while adding to the limited knowledge on prenatal pharmacological exposures as potential ASD risk factors, need to be balanced against the benefits of indicated medication use by pregnant mothers.
UR - http://www.scopus.com/inward/record.url?scp=84912027605&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84912027605&partnerID=8YFLogxK
U2 - 10.1007/s10803-014-2128-4
DO - 10.1007/s10803-014-2128-4
M3 - Article
C2 - 24803368
AN - SCOPUS:84912027605
SN - 0162-3257
VL - 44
SP - 2558
EP - 2567
JO - Journal of Autism and Developmental Disorders
JF - Journal of Autism and Developmental Disorders
IS - 10
ER -